Nov 4, 2025 07:05AM Prelude Therapeutics strikes $160M deal with Incyte, pauses SMARCA2 program

Nov 4, 2025 07:01AM Prelude Therapeutics secures $60M from Incyte option deal

Sep 23, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Prelude Therapeutics (PRLD)

Aug 14, 2025 04:22PM Prelude Therapeutics Incorporated (PRLD) Tops Q2 EPS by 7c

Apr 29, 2025 04:49AM Citizens JMP Reiterates Market Outperform Rating on Prelude Therapeutics (PRLD)

Apr 21, 2025 04:24AM Citizens JMP Reiterates Market Outperform Rating on Prelude Therapeutics (PRLD)

Mar 12, 2025 06:20AM Citizens JMP Reiterates Market Outperform Rating on Prelude Therapeutics (PRLD)

Dec 11, 2024 07:30AM Prelude Therapeutics Inc. (PRLD) Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymph

Nov 7, 2024 09:11AM Prelude Therapeutics Incorporated (PRLD) Tops Q3 EPS by 4c

Oct 9, 2024 07:31AM Prelude Therapeutics (PRLD) Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Sep 19, 2024 07:04AM H.C. Wainwright Upgrades Prelude Therapeutics (PRLD) to Buy, 'attractive entry point'

Sep 13, 2024 10:00AM Prelude Therapeutics Inc. (PRLD) Reports SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Sep 10, 2024 06:43AM H.C. Wainwright Reiterates Neutral Rating on Prelude Therapeutics (PRLD)

Sep 9, 2024 07:33AM Prelude Therapeutics (PRLD) Announces Publication of Abstract for Presentation at the European Society of Medical Oncology

Aug 12, 2024 09:05AM Prelude Therapeutics Incorporated (PRLD) Misses Q2 EPS by 4c

Jul 9, 2024 07:31AM Prelude Therapeutics Inc. (PRLD) Announces Clinical Collaboration with Mer zk to Evaluate PRT3789 plus KEYTRUDA

Jun 20, 2024 03:40AM Barclays Downgrades Prelude Therapeutics (PRLD) to Underweight